We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
On 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing antimalarial drugs.
